| アブストラクト | INTRODUCTION: There is limited knowledge about early-onset dementia (EOD) on fracture risk. METHODS: Individuals ages 50 to 64 were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (2012 to 2019). The association between EOD and fractures and the association between cholinesterase inhibitors for EOD and fractures were evaluated using logistic regression analyses. RESULTS: We identified 13,614 EOD patients and 9,144,560 cognitively healthy individuals. The analysis revealed that EOD was associated with an increased risk of hip fractures (adjusted odds ratio, 95% confidence interval: 8.79, 7.37-10.48), vertebral fractures (1.73, 1.48-2.01), and major osteoporotic fractures (2.05, 1.83-2.30) over 3 years. The use of cholinesterase inhibitors was significantly associated with a reduction in hip fractures among EOD patients (0.28, 0.11-0.69). DISCUSSION: EOD patients have a higher risk of osteoporotic fractures than cognitively healthy individuals. The use of cholinesterase inhibitors may reduce the risk of hip fracture among EOD patients. HIGHLIGHTS: It is unknown whether early-onset dementia (EOD) increases the risk of fractures. We identified 13,614 individuals with EOD using a nationwide administrative database. Patients with EOD have a higher risk of hip, vertebral, and major osteoporotic fractures. The use of cholinesterase inhibitors may reduce hip fracture among patients with EOD. |
|---|
| 投稿者 | Matsumoto, Shoya; Hosoi, Tatsuya; Yakabe, Mitsutaka; Fujimori, Kenji; Tamaki, Junko; Nakatoh, Shinichi; Ishii, Shigeyuki; Okimoto, Nobukazu; Akishita, Masahiro; Iki, Masayuki; Ogawa, Sumito |
|---|
| 組織名 | Department of Geriatric Medicine, Graduate School of Medicine, The University of;Tokyo, Bunkyo-ku, Tokyo, Japan.;Department of Health Administration and Policy, Tohoku University School of;Medicine, Sendai, Miyagi, Japan.;National Database Japan-Osteoporosis Management (NDBJ-OS) Study Group, Kindai;University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.;Department of Hygiene and Public Health, Faculty of Medicine, Osaka Medical and;Pharmaceutical University, Takatsuki, Osaka, Japan.;Department of Orthopedic Surgery, Asahi General Hospital, Shimo-Nikawa-gun,;Toyama, Japan.;Department of Regulatory Science, School of Pharmacy, Tokyo University of;Pharmacy and Life Sciences, Hachiouji, Tokyo, Japan.;Okimoto Clinic, Kure, Hiroshima, Japan.;Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. |
|---|
